Valeant On Track To File Retigabine For Epilepsy In 2008
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Valeant Pharmaceuticals is on track to file for marketing approval of its first-in-class neuronal potassium channel opener retigabine for treatment of epilepsy in the U.S. and EU in mid-2008. The firm announced Nov. 27 that it has completed enrollment in a second Phase III study of the drug